MOTS-c vs NAD+: What Does the Research Actually Show?

MOTS-c and NAD+ often appear in the same conversations about ageing, metabolism, mitochondrial function and cellular energy. That can make them sound like two versions of the same thing. They are not.

MOTS-c is a small peptide encoded by mitochondrial DNA, while NAD+ is a molecule found throughout cells that plays a central role in energy metabolism, redox reactions and several signalling pathways. Their biology overlaps in places, particularly around mitochondrial function and metabolic stress, but they work through very different mechanisms.

The distinction matters when looking at the research. MOTS-c is still an emerging area, with much of the evidence coming from cellular, animal and observational studies. NAD+ biology has been studied for considerably longer, and there is now a growing body of human research, particularly around NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

What is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is a 16-amino-acid mitochondrial-derived peptide produced by the mitochondrial genome.

Unlike many standard peptides encoded by nuclear DNA, MOTS-c is encoded by mitochondrial DNA. Research suggests it can act as a signalling molecule involved in metabolic regulation and the cellular stress response. Under specific conditions, MOTS-c has also been observed to move from the mitochondria to the nucleus, where it may impact gene expression.

This is one reason MOTS-c has attracted interest in ageing research. Experimental studies have linked it with pathways involved in glucose metabolism, energy balance, oxidative stress and cellular stress responses.

There is also evidence that exercise can affect circulating mitochondrial-derived peptides. In a human study, acute endurance and resistance exercise were associated with changes in circulating MOTS-c and humanin, although findings in this area are still developing.

It is worth keeping the evidence level in mind, though. A mechanism observed in a cell or animal model does not automatically translate into a proven effect in humans.

What is NAD+?

NAD+, or nicotinamide adenine dinucleotide, is not a peptide. It is a coenzyme present in cells and is essential for numerous biochemical reactions.

One of its best-known roles is helping cells transfer energy during metabolism. NAD+ also participates in redox reactions and acts as a substrate for enzymes involved in processes such as DNA repair and cellular signalling. Because of these functions, changes in NAD+ availability can affect several interconnected cellular pathways rather than one isolated function.

NAD+ levels and metabolism have become particularly intriguing in ageing research. Rather than simply giving people NAD+ itself, many human studies have investigated compounds that the body can use to support NAD+ production, including NR and NMN.

That distinction is important. Research on an NAD+ precursor should not automatically be described as evidence for direct NAD+ supplementation.

MOTS-c and NAD+ do have some common ground

Although they are different molecules, there is an obvious point of overlap: both are being investigated in relation to cellular metabolism and mitochondrial biology.

MOTS-c appears to function more like a signalling molecule involved in metabolic adaptation and stress responses. NAD+, meanwhile, is part of the basic biochemical machinery that allows cells to manage energy and redox reactions.

Research on MOTS-c has linked the peptide with pathways such as AMPK and other mechanisms involved in metabolic regulation. Recent reviews also describe possible roles in oxidative stress, inflammation and mitochondrial quality control, although several of these findings remain based mainly on experimental models.

NAD+ research is broader because the molecule is involved in a large number of cellular processes. Increasing NAD+-related metabolites can alter the availability of NAD+ within cells, but the biological outcome depends on factors including tissue, metabolic state, age and the way the intervention is delivered.

Therefore, while both sit within the wider field of mitochondrial and metabolic research, they should not be treated as interchangeable approaches.

Where the human evidence currently stands

This is probably the most significant difference between MOTS-c and NAD+.

MOTS-c research remains relatively early. Human studies have examined circulating MOTS-c levels and their relationship with conditions or physiological states. For example, a 2025 study involving 77 participants reported lower serum MOTS-c levels in people with more severe obstructive sleep apnoea. Findings such as this are useful for understanding associations, but they do not show that administering MOTS-c would prevent or treat the condition.

There is also promising laboratory research. A recent study using human skeletal muscle cells found that MOTS-c helped preserve myotube size and altered several signalling responses under dexamethasone-induced muscle atrophy conditions. Again, these findings are interesting mechanistic evidence, not the same thing as a clinical treatment result in people.

NAD+ research has moved further into human studies. A 2026 systematic review identified 33 human intervention studies among 113 eligible human and rodent studies examining NAD-related compounds. NR and NMN generally increased NAD-related biomarkers, but effects on functional and health-related outcomes were much less consistent.

That is an important distinction. Raising a biomarker is not necessarily the same as producing a meaningful clinical benefit.

Does that make NAD+ more established than MOTS-c?

In terms of human research, the evidence base is currently more developed for NAD+-related interventions, particularly NR and NMN.

That does not mean every claim made about NAD+ has been demonstrated. The 2026 systematic review found that clinical outcomes varied considerably, with some studies showing limited or endpoint-specific effects. The review also noted that there were no eligible outcome trials evaluating intravenous NAD+ specifically for anti-ageing or wellness purposes.

MOTS-c is at an earlier stage. Its biology is attracting considerable interest, but there is still a relatively small amount of controlled human intervention research compared with the wider NAD+ field.

This situation is where online discussions can get ahead of the science. Promising mechanisms are worth investigating, but they are not a substitute for properly designed clinical trials.

MOTS-c vs NAD+: why the distinction matters

The simplest way to think about the two is that they belong to different parts of cellular biology.

MOTS-c is a mitochondrial-derived signalling peptide being investigated for its possible role in metabolic adaptation, stress responses and mitochondrial regulation.

NAD+ is a fundamental cellular coenzyme involved in energy metabolism, redox balance and signalling. Research into NAD+ often focuses on ways to influence its levels through precursors such as NR and NMN.

There is some biological overlap, but neither should be viewed as a direct replacement for the other.

For researchers, the more useful question is often not which molecule is “better,” but what biological mechanism is being investigated, what type of evidence supports it, and whether the findings have been reproduced in humans.

The research is still moving

MOTS-c is a major example of how mitochondrial biology has grown beyond the traditional view of mitochondria simply being the cell’s energy-producing structures. Its potential role as a signalling molecule has opened up several areas of research, particularly in metabolism and cellular stress.

NAD+ research, meanwhile, has a longer history and a substantially larger human evidence base. Even so, the clinical picture is not straightforward. Increasing NAD+ or NAD-related metabolites is biologically measurable, but whether that translates into meaningful improvements in health or ageing outcomes remains an active area of research.

For now, MOTS-c and NAD+ are best understood as two distinct research subjects with overlapping interests in mitochondrial function, metabolism and cellular ageing. The science behind both is developing, but the strength and type of evidence are not the same.

That difference is easy to lose in simplified comparisons. It is also one of the most important things to keep in mind when reading new studies in this field.